Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 18, 2021

View Archived Issues

Vaccine shows efficacy against Lyme disease in guinea pigs

Novel protein ACE2 1-618-DDC-ABD protects against lethal SARS-CoV-2 infection

Preclinical results presented on a novel conditionally activated IFN-alpha INDUKINE molecule

Stanford researchers identify means of targeting RBM20 for ameliorating diseased cardiomyocytes

PCC-1, an orally active HPK1 inhibitor with strong antitumor activity

Novel STING agonist RVU-27065 shows potency in EMT6 breast cancer model

Medshine Discovery discloses new MAPK inhibitors

p53-PHLDA3-Akt signaling as novel therapeutic target in heart failure

Gasherbrum Bio patents GLP-1 receptor agonists

Innate checkpoint inhibitor ASD-141 inhibits tumor growth in colon cancer models

GNT Biotech & Medicals presents new HDAC inhibitors

Betta Pharmaceuticals identifies PTPN11 inhibitors

Shanghai Licheng Biotechnology divulges CLRN3-targeting nucleic acids

Novel acute lung injury murine model unveils neuronal damage

TOTUM-854 prevents the development of experimental arterial hypertension

Abintus to use Memorial Sloan's 1XX technology with CAR-X products

CoImmune enters research collaboration with Yeda Research and Development on SIN technology

Emultech and Osteo-Pharma establish Bone-Tech joint venture for osteoarthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...